DE69217056T2 - Taxan-Derivate enthaltende Arzneimittel - Google Patents

Taxan-Derivate enthaltende Arzneimittel

Info

Publication number
DE69217056T2
DE69217056T2 DE69217056T DE69217056T DE69217056T2 DE 69217056 T2 DE69217056 T2 DE 69217056T2 DE 69217056 T DE69217056 T DE 69217056T DE 69217056 T DE69217056 T DE 69217056T DE 69217056 T2 DE69217056 T2 DE 69217056T2
Authority
DE
Germany
Prior art keywords
taxane derivatives
medicines containing
containing taxane
derivatives
solutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69217056T
Other languages
English (en)
Other versions
DE69217056T3 (de
DE69217056T4 (de
DE69217056D1 (de
Inventor
Jean-Pierre Bastart
Thierry Dupechez
Jean-Louis Fabre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9414814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69217056(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Publication of DE69217056T2 publication Critical patent/DE69217056T2/de
Application granted granted Critical
Publication of DE69217056T4 publication Critical patent/DE69217056T4/de
Publication of DE69217056T3 publication Critical patent/DE69217056T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
DE69217056T 1991-07-08 1992-07-03 Taxan-Derivate enthaltende Arzneimittel Expired - Lifetime DE69217056T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9108527 1991-07-08
FR9108527A FR2678833B1 (fr) 1991-07-08 1991-07-08 Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
PCT/FR1992/000625 WO1993000929A1 (fr) 1991-07-08 1992-07-03 Nouvelles compositions a base de derives de la classe des taxanes

Publications (3)

Publication Number Publication Date
DE69217056T2 true DE69217056T2 (de) 1997-06-05
DE69217056T4 DE69217056T4 (de) 2009-08-20
DE69217056T3 DE69217056T3 (de) 2010-04-22

Family

ID=9414814

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69223624T Expired - Fee Related DE69223624T2 (de) 1991-07-08 1992-07-03 Taxan-derivate enthaltende arzneimittel
DE69217056A Expired - Fee Related DE69217056D1 (de) 1991-07-08 1992-07-03 Taxan-Derivate enthaltende Arzneimittel
DE69217056T Expired - Lifetime DE69217056T3 (de) 1991-07-08 1992-07-03 Taxan-Derivate enthaltende Arzneimittel

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69223624T Expired - Fee Related DE69223624T2 (de) 1991-07-08 1992-07-03 Taxan-derivate enthaltende arzneimittel
DE69217056A Expired - Fee Related DE69217056D1 (de) 1991-07-08 1992-07-03 Taxan-Derivate enthaltende Arzneimittel

Country Status (28)

Country Link
US (1) US5403858A (de)
EP (4) EP0593601B1 (de)
JP (2) JP2595458B2 (de)
KR (1) KR0136722B1 (de)
AT (2) ATE161193T1 (de)
CA (2) CA2102777C (de)
CZ (1) CZ280965B6 (de)
DE (3) DE69223624T2 (de)
DK (2) DK0593601T3 (de)
ES (2) ES2110003T3 (de)
FI (2) FI111807B (de)
FR (1) FR2678833B1 (de)
GE (1) GEP19991517B (de)
GR (2) GR3022355T3 (de)
HK (1) HK1006207A1 (de)
HU (1) HU217839B (de)
IE (2) IE80461B1 (de)
MX (2) MX9203960A (de)
NO (2) NO307205B1 (de)
PL (1) PL169372B1 (de)
RU (1) RU2134123C1 (de)
SE (1) SE0593656E5 (de)
SG (1) SG80541A1 (de)
SK (1) SK279946B6 (de)
TW (2) TW577752B (de)
WO (2) WO1993000929A1 (de)
YU (1) YU48913B (de)
ZA (1) ZA924999B (de)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714512A (en) * 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5750561A (en) * 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
GB2269319B (en) * 1992-08-03 1997-04-09 Bristol Myers Squibb Co Methods for administration of taxol
DK0835657T3 (da) * 1992-11-27 2005-01-10 Mayne Pharma Usa Inc Stabil, injicerbar paclitaxelsammensætning
JPH06157330A (ja) * 1992-11-27 1994-06-03 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物，その製造法と用途
US5684169A (en) * 1992-11-27 1997-11-04 Ensuiko Sugar Refining Co., Ltd. Cyclodextrin inclusion complex of taxol, and method for its production and its use
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
DK1155689T3 (da) * 1993-07-19 2006-11-20 Angiotech Pharm Inc Antiangiogene stents og fremgangsmåder til fremstilling heraf
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5686110A (en) * 1994-06-02 1997-11-11 Enzon, Inc. Water soluble complex of an alkyl or olefinic end capped polyalkylene oxide and a water insoluble substance
EP0769936A1 (de) * 1994-07-22 1997-05-02 G.D. Searle & Co. Selbstemulgierendes system zur arzneistoffabgabe
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CN1209059A (zh) * 1995-12-21 1999-02-24 基因实验室技术有限公司 紫杉烷类组合物及方法
KR100191446B1 (ko) * 1996-05-02 1999-06-15 송영욱 파클리탁셀 함유 전신성 홍반성 낭창치료제
WO1998053810A1 (en) * 1997-05-30 1998-12-03 Man Woo Han Pharmaceutical injection solution containing taxol
KR100358934B1 (ko) * 1996-09-13 2003-01-29 주식회사한국신약 탁솔을함유한주사용약제조성물
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
KR20010020342A (ko) 1997-04-28 2001-03-15 자끄 사비나 종양치료용 맥관형성 길항제의 아데노바이러스-매개 종양내 전달방법
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US7208010B2 (en) * 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US20040254635A1 (en) * 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7208011B2 (en) * 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US7314637B1 (en) 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
WO2000023070A1 (en) 1998-10-20 2000-04-27 Ben Venue Laboratories, Inc. Process for purification of solvents useful in the preparation of pharmaceutical compositions
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6290673B1 (en) 1999-05-20 2001-09-18 Conor Medsystems, Inc. Expandable medical device delivery system and method
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
WO2002032347A2 (en) 2000-10-16 2002-04-25 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
PL203300B1 (pl) 2000-10-31 2009-09-30 Akad Medyczna Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego
WO2002043765A2 (en) * 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US6964680B2 (en) * 2001-02-05 2005-11-15 Conor Medsystems, Inc. Expandable medical device with tapered hinge
US20040073294A1 (en) * 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
KR20020079239A (ko) * 2001-04-14 2002-10-19 이언식 학습기
US20040249443A1 (en) * 2001-08-20 2004-12-09 Shanley John F. Expandable medical device for treating cardiac arrhythmias
US7056338B2 (en) * 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
US20030101058A1 (en) * 2001-11-26 2003-05-29 Kenneth Liou Voice barcode scan device
JP2005515187A (ja) * 2001-11-26 2005-05-26 スーパージェン インコーポレイテッド ポリオキシエチル化ひまし油を使用する医薬組成物の調製方法
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
EP1490090A4 (de) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc Wirkstoff-abgabesystem und verfahren zum schutz und zur verabreichung von wirkstoffen
US8313760B2 (en) * 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
CN100341589C (zh) 2002-05-24 2007-10-10 血管技术国际股份公司 用于涂覆医用植入物的组合物和方法
US20040127976A1 (en) * 2002-09-20 2004-07-01 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
CA2499594A1 (en) * 2002-09-20 2004-04-01 Conor Medsystems, Inc. Expandable medical device with openings for delivery of multiple beneficial agents
EA200501252A1 (ru) 2003-02-03 2006-02-24 Неофарм, Инк. Липосомальная композиция, способ ее получения и лекарственное средство на ее основе (варианты)
JP5596896B2 (ja) 2003-03-28 2014-09-24 イノヴェイショナル・ホールディングズ・エルエルシー 有益な薬剤の濃度勾配を有する、移植可能な医療装置の形成方法
US7169179B2 (en) * 2003-06-05 2007-01-30 Conor Medsystems, Inc. Drug delivery device and method for bi-directional drug delivery
US7785653B2 (en) * 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
CA2536242A1 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Implantable sensors and implantable pumps and anti-scarring agents
AU2005100176A4 (en) * 2005-03-01 2005-04-07 Gym Tv Pty Ltd Garbage bin clip
CA2611592A1 (en) * 2005-06-17 2006-12-21 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
GB0517092D0 (en) * 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
BRPI0600194A (pt) 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
WO2008026048A2 (en) * 2006-08-31 2008-03-06 Wockhardt Research Centre Stable injectable pharmaceutical compositions of docetaxel
EP1946747A1 (de) * 2007-01-17 2008-07-23 Sandoz AG Taxanderivat enthaltende pharmazeutische Zusammensetzung von verbesserter Stabilität
CZ200756A3 (cs) * 2007-01-23 2008-07-30 Heaton, A. S. Dvousložková farmaceutická kompozice obsahující taxan
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
US20080319048A1 (en) * 2007-06-22 2008-12-25 Scidose Llc Solubilized formulation of docetaxel without tween 80
US20090076127A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched larotaxel
FR2922107B1 (fr) 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
ES2344674B1 (es) 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
EP2204167A1 (de) 2009-01-05 2010-07-07 Azad Pharma AG Pharmazeutische Mikroemulsion zur Prävention von supramolekularer Aggregation von ampiphilen Molekülen
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
CN102038635A (zh) 2009-10-23 2011-05-04 天津天士力集团有限公司 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
CN102970990A (zh) 2010-05-03 2013-03-13 帝国制药美国公司 非水性紫杉烷前-乳剂制剂以及制备和使用该制剂的方法
WO2012156999A1 (en) 2011-05-19 2012-11-22 Manu Chaudhary Ready to use docetaxel formulation
US9623059B2 (en) 2011-09-08 2017-04-18 New York University Oncolytic herpes simplex virus and therapeutic uses thereof
US9745631B2 (en) 2011-12-20 2017-08-29 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
JP2013194009A (ja) * 2012-03-21 2013-09-30 Nipro Corp ドセタキセル製剤
CA2874521A1 (en) 2012-05-24 2013-11-28 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
WO2014014518A1 (en) 2012-07-18 2014-01-23 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
WO2014013903A1 (ja) * 2012-07-19 2014-01-23 富士フイルム株式会社 タキサン系活性成分含有液体組成物、その製造方法及び液体製剤
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
EP2777691A1 (de) * 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Reinigung der flüssigen Hilfsstoffen
WO2014149871A1 (en) 2013-03-14 2014-09-25 Icahn School Of Medicine At Mount Sinai Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer
WO2015050844A1 (en) 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
BR112016021717A2 (pt) 2014-03-21 2018-07-10 Abbvie Inc anticorpos anti-egfr e conjugados anticorpo-fármaco
WO2015149006A2 (en) 2014-03-27 2015-10-01 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
US10967015B2 (en) 2015-06-15 2021-04-06 New York University Method of treatment using oncolytic viruses
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
PL3458479T3 (pl) 2016-06-08 2021-07-26 Abbvie Inc. Przeciwciała anty-b7-h3 i koniugaty przeciwciało-lek
JP2019524651A (ja) 2016-06-08 2019-09-05 アッヴィ・インコーポレイテッド 抗ｃｄ９８抗体及び抗体薬物コンジュゲート
CN109562168A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗cd98抗体及抗体药物偶联物
JP2019521973A (ja) 2016-06-08 2019-08-08 アッヴィ・インコーポレイテッド 抗ｂｈ７−ｈ３抗体及び抗体薬物コンジュゲート
AU2017279539A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
JP6292267B2 (ja) * 2016-09-13 2018-03-14 ニプロ株式会社 ドセタキセル製剤
WO2019047812A1 (zh) 2017-09-07 2019-03-14 深圳信立泰药业股份有限公司 多西他赛共缀物的药物组合物及制备方法
JP2018115178A (ja) * 2018-03-15 2018-07-26 ニプロ株式会社 ドセタキセル製剤
CA3109440A1 (en) 2018-09-05 2020-03-12 Emcure Pharmaceuticals Ltd. Stable ready-to-use carmustine pharmaceutical composition
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206221A (en) * 1979-01-03 1980-06-03 The United States Of America As Represented By The Secretary Of Agriculture Cephalomannine and its use in treating leukemic tumors
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof

Also Published As

Publication number Publication date
EP0593656B1 (de) 1997-01-22
EP0593601A1 (de) 1994-04-27
ES2096091T3 (es) 1997-03-01
CA2102777A1 (fr) 1993-01-09
NO934610D0 (no) 1993-12-14
FI940073A (fi) 1994-01-07
FI940074A (fi) 1994-01-07
SE0593656T6 (de) 1997-01-22
FR2678833B1 (fr) 1995-04-07
EP0593601B1 (de) 1997-12-17
DE69223624T2 (de) 1998-04-23
ES2096091T7 (es) 2010-03-31
SE0593656E5 (sv) 2009-10-07
NO934609L (no) 1993-12-14
DK0593656T3 (da) 1997-02-10
CA2102777C (fr) 2004-09-07
AU2278792A (en) 1993-02-11
MX9203960A (es) 1993-01-01
IE922213A1 (en) 1993-01-13
YU48913B (sh) 2002-11-15
FI940073A0 (fi) 1994-01-07
IE80548B1 (en) 1998-09-09
EP0593656B3 (de) 2009-10-07
FI111807B (fi) 2003-09-30
PL169372B1 (en) 1996-07-31
DK0593601T3 (da) 1998-02-09
IE80461B1 (en) 1998-07-29
ATE147992T1 (de) 1997-02-15
NO307205B1 (no) 2000-02-28
NO934610L (no) 1993-12-14
JPH06507914A (ja) 1994-09-08
SG80541A1 (en) 2001-05-22
CZ3294A3 (en) 1995-02-15
CZ280965B6 (cs) 1996-05-15
FI940074A0 (fi) 1994-01-07
SE0593656T3 (de) 1997-01-22
DE69217056T3 (de) 2010-04-22
RU2134123C1 (ru) 1999-08-10
MX9203959A (es) 1993-01-01
WO1993000928A1 (fr) 1993-01-21
US5403858A (en) 1995-04-04
TW577752B (en) 2004-03-01
HU9400052D0 (en) 1994-05-30
DE69217056T4 (de) 2009-08-20
ES2110003T3 (es) 1998-02-01
CA2102778C (fr) 2004-04-20
EP0522936A1 (de) 1993-01-13
CA2102778A1 (fr) 1993-01-09
GEP19991517B (en) 1999-03-05
GR3025714T3 (en) 1998-03-31
ATE161193T1 (de) 1998-01-15
FI111808B (fi) 2003-09-30
JPH06507913A (ja) 1994-09-08
AU666859B2 (en) 1996-02-29
DE69217056D1 (de) 1997-03-06
HU217839B (hu) 2000-04-28
SK1594A3 (en) 1994-10-05
JP2595458B2 (ja) 1997-04-02
WO1993000929A1 (fr) 1993-01-21
GR3022355T3 (en) 1997-04-30
EP0522937A1 (de) 1993-01-13
HK1006207A1 (en) 1999-02-12
HUT65960A (en) 1994-08-29
DE69223624D1 (de) 1998-01-29
IE922212A1 (en) 1993-01-13
EP0593656A1 (de) 1994-04-27
FR2678833A1 (fr) 1993-01-15
KR0136722B1 (ko) 1998-04-25
SK279946B6 (sk) 1999-06-11
NO934609D0 (no) 1993-12-14
YU67692A (sh) 1995-12-04
DK0593656T5 (da) 2010-01-11
ZA924999B (en) 1993-04-28
NO307206B1 (no) 2000-02-28
TW495362B (en) 2002-07-21

Similar Documents

Publication Publication Date Title
DE69217056D1 (de) Taxan-Derivate enthaltende Arzneimittel
DE59009351D1 (de) Neue arylpyridazine, ihre herstellung, verwendung und sie enthaltende arzneimittel.
FI891552A0 (fi) Anti-inflammatorisk emulsionssalvakomposition.
DE515995T1 (de) N-(5-thioxo-l-propyl)-l-cystein und derivate, deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen.
DE3578597D1 (de) 4-phenylphthalazin-derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
ATE145333T1 (de) Hirudin enthaltende orale arzneimittel
ITMI911845A1 (it) Uso dei derivati dell'acido benzimidazolin-2-oxo-1-carbossilico.
DE3880348T2 (de) N-substituierte alpha-mercaptomethylbenzenpropanamid-derivate, ihre herstellung, ihre verwendung als arzneimittel und diese enthaltende zusammensetzungen.
ATE959T1 (de) 2'-(ortho-chlor-benzoyl), 4'-chlor-glycinanilid-derivate, ihre herstellung und ihre verwendung als arzneimittel.
FI883793A (fi) Ny farmaceutisk komposition i form av granuler och foerfarande foer framstaellning av granuler.
ATE8622T1 (de) 3-aminopropoxyaryl-derivate, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE1011T1 (de) 5-fluoruracil-derivate, deren herstellung und ihre pharmazeutischen zusammensetzungen.
ATE6062T1 (de) Pleuromutilin-derivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ATE10191T1 (de) 1-sulfo-2-azetidinon-derivate, ihre herstellung und pharmazeutische zusammensetzungen.